Related Experiment Videos
Cryptococcosis in renal transplant patients
Proceedings of the Clinical Dialysis and Transplant Forum
|November 19, 1976
Summary
Cryptococcal infections in transplant patients require prompt diagnosis and treatment using available antifungal drugs. Careful monitoring is essential to manage inevitable drug toxicity and optimize therapeutic levels for effective outcomes.
Area of Science:
- Infectious Diseases
- Transplant Medicine
- Pharmacology
Background:
- Cryptococcal infections pose a significant risk to transplant recipients.
- Early diagnosis and effective treatment are crucial for patient survival.
- Current antifungal therapies require careful management to balance efficacy and toxicity.
Purpose of the Study:
- To outline strategies for the diagnosis and treatment of cryptococcal infections in transplant patients.
- To emphasize the importance of monitoring for and minimizing drug-related toxicities.
- To highlight the role of antifungal drug assays and therapeutic drug monitoring.
Main Methods:
- Review of current diagnostic and therapeutic approaches for cryptococcal infections.
- Discussion of potential drug-related toxicities, including nephrotoxicity and hematologic effects.
- Emphasis on the utility of antifungal drug level monitoring in conjunction with in vitro susceptibility testing.
Main Results:
- Cryptococcal infections in transplant patients are diagnosable and treatable with existing antifungal agents.
- Drug-related toxicities, primarily nephrotoxicity and hematologic issues, are anticipated.
- Antifungal drug assays are available and support therapeutic drug monitoring for safety and efficacy.
Conclusions:
- Aggressive and innovative use of available antifungal drugs can effectively manage cryptococcal infections in transplant recipients.
- Close patient monitoring is vital to mitigate inevitable drug toxicities.
- Therapeutic drug monitoring, guided by in vitro susceptibility data, optimizes antifungal treatment outcomes.